Maze Therapeutics
secret to health
Maze Corporate Presentation October 2022
view our pipeline pipeline

latest press releases

September 22, 2022
Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors
August 31, 2022
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease
February 24, 2022
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD

latest media coverage

December 16, 2022
Updated: Maze reveals positive first look at PhI Pompe disease candidate
June 29, 2022
LifeSci 2nd Annual Genetic Medicines Symposium 2022
March 23, 2021
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
December 7, 2020
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
December 7, 2020
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
January 6, 2020
Top Life Sciences Startups to Watch in 2020
February 28, 2019
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
February 28, 2019
MIT Technology Review: The secret to a new drug could be hiding in your genes

    want to get a hold of a representative?

    Jillian Connell
    Maze Therapeutics
    jconnell@mazetx.com

    media inquires

    Katie Engleman
    1AB
    katie@1abmedia.com

    Contact Us